Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-10T10:33:39.435Z Has data issue: false hasContentIssue false
  • English
  • Français

Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report

Published online by Cambridge University Press:  29 November 2013

N. Subramanian  and
M. Doran
N. Subramanian*
Affiliation:
Senior Registrar in Psychiatry, National Drug Treatment Centre, Dublin & Clare Mental Health Services, Ennis, Co.Clare, Ireland
M. Doran
Affiliation:
Consultant Psychiatrist, National Drug Treatment Centre, Dublin, Ireland
*
*Address for correspondence: Dr N. Subramanian, Senior Registrar in Psychiatry, National Drug Treatment Centre, Dublin & Clare Mental Health Services, Ennis, Co.Clare, Ireland. (Email: addiction.narayanan@gmail.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe a 38-year-old woman who developed symptoms of hallucinogen persisting perception disorder (HPPD) after using lysergic acid diethylamide (LSD) once and continued to have symptoms of HPPD for nearly 17 years, although she did not use LSD after her first use. The symptoms of HPPD were temporally related to her first LSD use and she responded well to risperidone within a few weeks of commencing on the same. Although different medications have been tried in the management of HPPD including risperidone, olanzapine, clonidine, fluoxetine, sertraline, benzodiazepines and anti-epileptic medications, none have been proven to be the definitive medication of choice in the treatment of HPPD. Furthermore, there have been case reports suggesting worsening of symptoms with risperidone; however, the response to risperidone in our patient suggests the possibility of its effectiveness in the management of HPPD symptoms in some patients.

Keywords

Drug-induced perception disorderhallucination persisting perception disorderhallucinogensHPPDLSDrisperidone
Type
Case Report
Information
Irish Journal of Psychological Medicine , Volume 31 , Issue 1 , March 2014 , pp. 47 - 49
Copyright
Copyright © College of Psychiatrists of Ireland 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abraham, HD (1983). Visual phenomenology of the LSD flashback. Archives of General Psychiatry 40, 884–889.Google Scholar
Aldurra, G, Crayton, JW (2001). Improvement of hallucinogen induced persistent perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. Journal of Clinical Pharmacology 21, 343–344.Google Scholar
American Psychiatric Association (APA) (2013). DSM-V: Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association: Washington, DC.Google Scholar
Barron, SP, Lowinger, P, Ebner, E (1970). A clinical examination of chronic LSD use in the community. Comprehensive Psychiatry 11, 69–79.Google Scholar
Batzer, W, Ditzler, T, Brown, C (1999). LSD use and flashbacks in alcoholic patients. Journal of Addiction Disorder 18, 57–63.Google Scholar
Casa, B, Bosio, A (2005). Levetiracetam efficacy in hallucinogen persisting perception disorders: a prospective study. Journal of the Neurological Sciences 238, S504.Google Scholar
Cooper, HA (1955). Hallucinogenic drugs. Lancet 268, 1078.Google Scholar
Espiard, ML, Lecardeur, L, Abadie, P, Halbecq, I, Dollfus, S (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European Psychiatry 20, 458–460.Google Scholar
Gaillard, MC, Borruat, FX (2003). Persisting visual hallucinations and illusions previously drug-addicted patients. Klin Monbl Augenheilkd 220, 176–178.Google Scholar
Gonzalez-Maeso, J, Sealfon, S (2006). Hormone signaling via G protein-coupled receptors. In Endocrinology (ed. L. C. DeGroot and J. L. Jameson), pp. 177–203. Elsevier: Amsterdam.Google Scholar
Halpern, JH, Pope, HG (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence 69, 109–119.Google Scholar
Ikeda, A, Sekiguchi, K, Fujita, K, Yamadera, H, Koga, Y (2005). 5-methoxy-N, N-diisopropyltryptamine-induced flashbacks. American Journal of Psychiatry 162, 4.Google Scholar
Lerner, AG, Oyffe, I, Isaacs, G, Mircea, M (1997). Naltrexone treatment of hallucinogen persisting perception disorder. American Journal of Psychiatry 154, 437.Google Scholar
Lerner, AG, Finkel, B, Finkel, I, Oyffe, I, Merenzon, I, Sigal, M (1998). Clonidine treatment for hallucinogen persisting perception disorder. American Journal of Psychiatry 155, 1460.Google Scholar
Lerner, AG, Skladman, I, Kodesh, A, Sigal, M, Shufman, E (2001). LSD induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. Israel Journal of Psychiatry & Related Sciences 38, 133–136.Google Scholar
Talvik-Lofti, M, Nyberg, S, Nordstrom, AL, Ito, H, Halldin, C, Brunner, F, Farde, L. (2000). High 5HT-2A receptor occupancy in M100907-treated schizophrenia patients. Psychopharmacology 148, 400–403.CrossRefGoogle Scholar
Thurlow, J, Girvin, JP (1971). Use of anti-epileptic medication in treating flashbacks from hallucinogenic drugs. Canadian Medical Association Journal 105, 947–948.Google Scholar